Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770688 | 0.75 | DPP4 (0.33) | ADORA2ADPP4 | |
| SCHEMBL19925111 | 0.74 | SLC40A1 (0.41) | — | |
| SCHEMBL29464371 | 0.74 | SLC40A1 (0.41) | — | |
| SCHEMBL19968759 | 0.67 | BACE1 (0.47) | NOS3NOS1NOS2ADORA2ADPP4 | |
| SCHEMBL29464888 | 0.67 | BACE1 (0.47) | NOS3NOS1NOS2ADORA2ADPP4 | |
| SCHEMBL28293934 | 0.67 | DPP4 (0.49) | NOS3NOS1NOS2DPP4 | |
| SCHEMBL23770695 | 0.66 | CYP1A2 (0.34) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL29464534 | 0.65 | PIK3CD (0.40) | PIK3CD | |
| SCHEMBL19925031 | 0.65 | PIK3CD (0.40) | PIK3CD | |
| SCHEMBL23770440 | 0.65 | SCN9A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |